FTH Company Profile and Key Details

Average 10-day trading volume of 101.54 thousand shares is in line with the 3-month average of 101.54 thousand, indicating normal recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $60.00 to $60.00. The high target offers 158.73% upside. The low target suggests 158.73% downside. The mean target is $60.00. This offers 158.73% upside. Faeth Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 15, 2026, missed forecasts by 21101.61%. The prior quarter beat by -22.25%. Over the last six quarters, Apple has recorded several small beats. These include -22.25% in March 30, 2026.

Our AI price prediction model suggests that Faeth Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Valuation shows Faeth Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.13. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $60.00, suggesting 158.73% upside.

Faeth Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.68. This means the shares are trading above this model’s fair value.

Faeth Therapeutics, Inc. (NASDAQ:FTH) closed at $23.19 USD, gaining $5.37 (30.13%) from the previous close of $17.82. The stock is currently mid-range between its 52-week high and low $6.33 and $36.76. With a market capitalization of about $31.12 million, Faeth Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.23). Key stats such as the average daily volume over the past year has been around 52.32 thousand shares, trading with heavier-than-usual volume. Headquartered in Rockville, MD, Faeth Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Anand Parikh, the company employs approximately 29 people and listed since August 11, 2014. Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways.

Faeth Therapeutics, Inc. trades at a P/E ratio of -0.13, slightly below the S&P 500 average, with a price-to-sales ratio of -5.45 and a price-to-book ratio of 0.13 suggesting the stock is closer to book value. The P/FCF stands at -1.1, also above market averages.